(ALMS) Alumis - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.916m USD | Total Return: 355% in 12m
Avg Turnover: 22.3M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 130.4% YoY
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
Leader, Confidence
Alumis Inc. (ALMS) is a clinical-stage biopharmaceutical firm specializing in targeted therapies for autoimmune and neuroinflammatory disorders. Its primary pipeline involves TYK2 inhibitors, including envudeucitinib for plaque psoriasis and systemic lupus erythematosus, and A-005, which targets the central nervous system. The company also advances lonigutamab for thyroid eye disease and programs focusing on IRF5 to address immune system dysfunction.
Operating within the biotechnology sector, Alumis utilizes a research-heavy business model characterized by high capital expenditures and long development cycles prior to commercialization. TYK2 inhibitors represent a competitive class of oral therapies designed to modulate cytokine signaling without the broad immunosuppression associated with older treatments. You can explore further valuation metrics and pipeline updates for this ticker on ValueRay.
- Phase 2 clinical data readouts for envudeucitinib determine near-term enterprise valuation
- Competitive TYK2 inhibitor landscape pressures market share potential in plaque psoriasis
- Lonigutamab trial progression dictates long-term growth prospects in thyroid eye disease
- Continued high R&D expenditure necessitates future equity financing and dilution
- Regulatory approval timelines for CNS-penetrant inhibitors impact institutional investor sentiment
| Net Income: -237.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.56 > 0.02 and ΔFCF/TA 55.91 > 1.0 |
| NWC/Revenue: 5.49k% < 20% (prev 808.2%; Δ 4.68k% < -1%) |
| CFO/TA -0.56 > 3% & CFO -376.2m > Net Income -237.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (125.1m) vs 12m ago 130.4% < -2% |
| Gross Margin: 58.39% > 18% (prev 0.88%; Δ 5.75k% > 0.5%) |
| Asset Turnover: 1.80% > 50% (prev 7.82%; Δ -6.02% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.69 (Total Current Assets 532.4m - Total Current Liabilities 70.9m) / Total Assets 671.6m |
| B: -1.48 (Retained Earnings -994.9m / Total Assets 671.6m) |
| C: -0.92 (EBIT TTM -431.0m / Avg Total Assets 466.4m) |
| D: -9.52 (Book Value of Equity -995.4m / Total Liabilities 104.6m) |
| Altman-Z'' = -16.53 = D |
| DSRI: 5.16 (Receivables 2.73m/1.29m, Revenue 8.40m/20.4m) |
| GMI: 1.51 (GM 58.39% / 88.28%) |
| AQI: 34.07 (AQ_t 0.16 / AQ_t-1 0.00) |
| SGI: 0.41 (Revenue 8.40m / 20.4m) |
| TATA: 0.21 (NI -237.4m - CFO -376.2m) / TA 671.6m) |
| Beneish M = 20.26 (Cap -4..+1) = D |
As of May 24, 2026, the stock is trading at USD 22.02 with a total of 518,405 shares traded.
Over the past week, the price has changed by -3.72%,
over one month by -14.95%,
over three months by -20.36% and
over the past year by +354.96%.
Alumis has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ALMS.
- StrongBuy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 39.9 | 81.2% |
P/B = 9.9886
Revenue TTM = 8.40m USD
EBIT TTM = -431.0m USD
EBITDA TTM = -427.5m USD
Long Term Debt = 31.2m USD (estimated: total debt 35.7m - short term 4.44m)
Short Term Debt = 4.44m USD (from shortTermDebt, last quarter)
Debt = 35.7m USD (from shortLongTermDebtTotal, last quarter) (leases 36.9m already included)
Net Debt = -487.3m USD (calculated: Debt 35.7m - CCE 522.9m)
Enterprise Value = 2.43b USD (2.92b + Debt 35.7m - CCE 522.9m)
Interest Coverage Ratio = unknown (Ebit TTM -431.0m / Interest Expense TTM 0.0)
EV/FCF = -6.44x (Enterprise Value 2.43b / FCF TTM -377.0m)
FCF Yield = -15.53% (FCF TTM -377.0m / Enterprise Value 2.43b)
FCF Margin = -4.49k% (FCF TTM -377.0m / Revenue TTM 8.40m)
Net Margin = -2.83k% (Net Income TTM -237.4m / Revenue TTM 8.40m)
Gross Margin = 58.39% ((Revenue TTM 8.40m - Cost of Revenue TTM 3.50m) / Revenue TTM)
Gross Margin QoQ = 49.97% (prev 55.05%)
Tobins Q-Ratio = 3.62 (Enterprise Value 2.43b / Total Assets 671.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 35.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -340.5m (EBIT -431.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.51 (Total Current Assets 532.4m / Total Current Liabilities 70.9m)
Debt / Equity = 0.06 (Debt 35.7m / totalStockholderEquity, last quarter 567.0m)
Debt / EBITDA = 1.14 (negative EBITDA) (Net Debt -487.3m / EBITDA -427.5m)
Debt / FCF = 1.29 (negative FCF - burning cash) (Net Debt -487.3m / FCF TTM -377.0m)
Total Stockholder Equity = 434.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -50.90% (Net Income -237.4m / Total Assets 671.6m)
RoE = -16.61% (Net Income TTM -237.4m / Total Stockholder Equity 1.43b)
RoCE = -29.50% (EBIT -431.0m / Capital Employed (Equity 1.43b + L.T.Debt 31.2m))
RoIC = -56.48% (negative operating profit) (NOPAT -340.5m / Invested Capital 602.8m)
WACC = 9.10% (E(2.92b)/V(2.95b) * Re(9.21%) + D(35.7m)/V(2.95b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 80.90 | Cagr: 47.90%
[DCF] Fair Price = unknown (Cash Flow -377.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.11 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.12 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.71 | Chg30d=+4.05% | Revisions=+33% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.72 | Chg30d=+6.38% | Revisions=+33% | Analysts=5
EPS current Year (2026-12-31): EPS=-2.90 | Chg30d=+5.16% | Revisions=+33% | GrowthEPS=+37.0% | GrowthRev=-71.3%
EPS next Year (2027-12-31): EPS=-2.95 | Chg30d=+8.64% | Revisions=+20% | GrowthEPS=-1.8% | GrowthRev=+269.4%
[Analyst] Revisions Ratio: +33%